FDA's Mail-Order Abortion Drug Rule Endangers Women and Lacks Scientific Justification
Source: Shawn Fleetwood. "Supreme Court Temporarily Revives FDA's Abortion Drug Rule." May 4, 2026. thefederalist.com
The Gist
The author argues that the FDA made a dangerous mistake in 2023 when it allowed abortion pills to be mailed without requiring women to see a doctor first. He claims this policy is based on bad science, has already caused harm, and should be stopped by the courts.
Conclusion
The FDA's 2023 rule allowing mifepristone to be mailed without in-person medical oversight is dangerous and should be blocked
Premises
- Mifepristone is a harmful abortion drug that euthanizes babies and can harm women
- The FDA's justifications for allowing remote dispensing were based on flawed or nonexistent data
- The rule has resulted in numerous illegal abortions in Louisiana and increased Medicaid costs for treating women harmed by mifepristone
- Federal courts have found three times that the FDA's progressive relaxation of mifepristone safeguards likely lacked basis in data and scientific literature
- The FDA itself admits the regulations had 'procedural deficits' and 'lack of adequate consideration'
- The original 2000 safety guardrails requiring in-person doctor examination were necessary protections that should not have been removed
- The Trump administration has been slow to establish effective safeguards despite pro-life campaign promises
Assumptions
- In-person medical oversight is necessary for safe abortion drug administration
- The FDA has a duty to base regulations on sound scientific data
- State governments have legitimate authority to challenge federal drug regulations that affect their citizens
- Abortion drugs pose inherent dangers that require strict medical supervision
- The 5th Circuit Court's legal reasoning is sound and should be upheld